Cleveland Biolabs, Inc. (CBLI:NASDAQ) Annual Reports & Investor Relations Material

Overview

Cleveland BioLabs, Inc. is a biotech company specializing in the development of innovative drugs for biodefense, tissue protection, and cancer treatment. The company's pipeline includes protectans and curaxins, two families of compounds with exciting potential in the pharmaceutical industry. Protectans are being developed as drug candidates to protect healthy tissues from acute stresses such as chemotherapy and ischemia, while curaxins are being developed as anticancer agents that could be used as stand-alone treatments or in combination with other therapies. Cleveland BioLabs is rapidly advancing its research in these areas and is poised to make a significant impact in the field of biotechnology.

Frequently Asked Questions

What is Cleveland Biolabs, Inc.'s ticker?

Cleveland Biolabs, Inc.'s ticker is CBLI

What exchange is Cleveland Biolabs, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Cleveland Biolabs, Inc.'s headquarters?

They are based in Buffalo, New York

How many employees does Cleveland Biolabs, Inc. have?

There are 51-200 employees working at Cleveland Biolabs, Inc.

What is Cleveland Biolabs, Inc.'s website?

It is http://www.cbiolabs.com

What type of sector is Cleveland Biolabs, Inc.?

Cleveland Biolabs, Inc. is in the Services sector

What type of industry is Cleveland Biolabs, Inc.?

Cleveland Biolabs, Inc. is in the Research Services industry

Who are Cleveland Biolabs, Inc.'s peers and competitors?

The following five companies are Cleveland Biolabs, Inc.'s industry peers:

- Bioanalytical Systems Inc.

- Myriad Genetics

- Cleveland Biolabs, Inc.

- Forrester Research

- National Research